Who are Septerna, Inc.'s main suppliers?

Septerna, Inc. (SEPN) key suppliers include: Eli Lilly and Company, Eli Lilly and Company, Novo Nordisk A/S, Novo Nordisk A/S, ORANY and 1 more. View the full supplier network at chainsifter.com/chain/SEPN.

Who are Septerna, Inc.'s major customers?

Septerna, Inc. (SEPN) key customers include: VERTEX, Eli Lilly and Company, Eli Lilly and Company, Novo Nordisk A/S, Novo Nordisk A/S and 2 more. View the full customer network at chainsifter.com/chain/SEPN.

What sector is Septerna, Inc. in?

Septerna, Inc. (SEPN) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

SEPN Supply Chain: Septerna, Inc. Supplier List & 15 Relationships

6Suppliers

7Customers

2Debt Items

20Related Chains

Septerna, Inc. Suppliers

Ticker	Name	Confidence	Evidence
LLY	Eli Lilly and Company	72%	ng and sales organization and have no experience as a company in commercializing products, and we may invest significant resources to develop these capabilities. If we are unable to establish marketi…
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from SEPN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from SEPN graph: ng and sales organization and have no…
NVO	Novo Nordisk A/S	72%	ng and sales organization and have no experience as a company in commercializing products, and we may invest significant resources to develop these capabilities. If we are unable to establish marketi…
NVO	Novo Nordisk A/S	72%	Reciprocal relationship from NVO graph: Reciprocal relationship from SEPN graph: ng and sales organization and have no experience as a company in commercializing products, and we may invest significa…
ORANY	ORANY	72%	rs. If our product candidates are approved, we expect that they will be priced at a significant premium over competitive generic products. Manufacturing and Supply We do not own or operate manufactur…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from SEPN graph: rs. If our product candidates are approved, we expect that they will be priced at a significant premium over competi…

Septerna, Inc. Customers

Ticker	Name	Confidence	Evidence
VERTEX	VERTEX	92%	For the three months ended March 31, 2025, our revenue was derived solely from research activities performed for Vertex under the Vertex Research Service Agreement.
LLY	Eli Lilly and Company	72%	ng and sales organization and have no experience as a company in commercializing products, and we may invest significant resources to develop these capabilities. If we are unable to establish marketi…
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from SEPN graph: ng and sales organization and have no experience as a company in commercializing products, and we may invest significa…
NVO	Novo Nordisk A/S	72%	ng and sales organization and have no experience as a company in commercializing products, and we may invest significant resources to develop these capabilities. If we are unable to establish marketi…
NVO	Novo Nordisk A/S	72%	Reciprocal relationship from NVO graph: Reciprocal relationship from SEPN graph: Reciprocal relationship from NVO graph: Reciprocal relationship from SEPN graph: Reciprocal relationship from NVO grap…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from SEPN graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from SEPN graph: Reciprocal relationship from ORAN…
ORANY	ORANY	72%	rs. If our product candidates are approved, we expect that they will be priced at a significant premium over competitive generic products. Manufacturing and Supply We do not own or operate manufactur…

Septerna, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
SEPN-DEBT	Debt stack $23.1M	90%	Market cache reports total debt of $23.1M.
SEPN-DEBT-12468	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2024-12-31.

Septerna, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Septerna, Inc..

Septerna, Inc. Ownership

Holder	Name	Confidence	Evidence
SEPN-OWNER-RA-CAPITAL-MANAGEMENT-L-P	RA CAPITAL MANAGEMENT, L.P.	90%	13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 125 tracked holders.

Septerna, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
NVO	Novo Nordisk A/S	100.00	2	['customer', 'supplier']
CRSP	CRISPR Therapeutics AG	100.00	2
BBOT	BridgeBio Oncology Therapeutics, Inc.	100.00	2
ORANY	ORANGE	100.00	1	['customer', 'supplier']
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
BYSI	BeyondSpring Inc.	100.00	2
AKTS	Aktis Oncology, Inc.	100.00	2
LGND	Ligand Pharmaceuticals Incorporated	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
VNDA	Vanda Pharmaceuticals Inc.	100.00	2
ALEC	Alector, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
FHTX	Foghorn Therapeutics Inc.	100.00	2
ACIU	AC Immune SA	100.00	2

Septerna, Inc. Supply Chain